

Arguments/Remarks

Claims 2-14, 21, and 23 are currently pending. Claim 18 has been cancelled, and 21 has been amended. Reconsideration of the amended claim set is respectfully requested.

Rejections Under 35 U.S.C. 112

Claims 18 and 21 have been rejected under 35 U.S.C. § 112, first paragraph as not being enabled. Applicants have amended claim 21 to a "breast tumor," and have canceled claim 18. Withdrawal and reconsideration are respectfully requested.

Rejections Under 35 USC §103 and Double Patenting Rejection

Claims 1-15, 18-21, and 23-26 are rejected under 35 USC §103 as being obvious over Furet et al (WO04/005282) (Furet '282), and rejected under obviousness-type double patenting over the U.S. equivalent of Furet '282, namely U.S. application no. 10/520,567. Applicants submit a terminal disclaimer to remove both references. Withdrawal and reconsideration are respectfully requested.


Double Patenting Rejection

Upon indication of allowable subject matter, applicant will address the double patenting rejection.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.  
220 Massachusetts Avenue  
Cambridge, MA 02139  
(617) 871-7347

  
\_\_\_\_\_  
Mark E. Baron  
Attorney for Applicant  
Reg. No. 46,150

Date: 17 May 2010